Does pt-141 nasal spray work, or just the injection?

Last updated 2026-07-24

Does PT-141 nasal spray actually work?

Nobody has good trial data on the nasal spray version, so the honest answer is: unproven. The drug that got FDA approval, bremelanotide, was studied and cleared as an injection under the brand name Vyleesi, not as a nasal spray ^[1]. The two phase 3 trials that mattered most for that approval, called RECONNECT, enrolled premenopausal women with hypoactive sexual desire disorder (HSDD) and had them self-inject bremelanotide under the skin before anticipated sexual activity ^[2]. Those trials found real, if modest, improvement. Women on bremelanotide had a mean increase in Female Sexual Function Index desire score of about 0.30 versus roughly 0.14 for placebo, and a drop in distress score (using the FSDS-DAO) of about -0.65 versus -0.35 for placebo ^[2]. Those numbers matter here because they're specific to the injected dose used in the trial, not to a spray formulation. Earlier development work did test bremelanotide as a nasal spray. A 2006 pharmacology paper covers this route ^[3], and it's part of why some vendors still sell PT-141 branded as nasal spray today. But that early nasal program was shelved. The reason usually cited in the literature is that intranasal dosing caused a concerning rise in blood pressure in some subjects, which pushed development toward the subcutaneous injection that eventually became Vyleesi ^[4]. So the nasal route isn't some overlooked shortcut. It's the version the drug's own developers moved away from.

What is PT-141 and how is it different from Viagra-type drugs?

PT-141 is the research name for bremelanotide, a synthetic peptide that activates melanocortin receptors in the brain, mainly MC4R ^{[5] [6]}. That's the single most important thing to understand about it: this is a brain drug, not a blood-flow drug. Sildenafil (Viagra) and similar drugs work on the vascular system, relaxing smooth muscle so blood pools in genital tissue. That mechanism is peripheral. Bremelanotide works upstream of that, in the central nervous system, where melanocortin signaling is thought to influence sexual motivation and arousal pathways directly ^[7]. A CNS Spectrums review describes this central mechanism as the basis for bremelanotide's effect on desire in premenopausal women with HSDD ^[7]. This distinction explains a lot about why bremelanotide's side effect profile looks different too. Melanocortin receptors also sit in pathways tied to appetite, pigmentation, and blood pressure regulation, which is part of why nausea and blood pressure changes show up as known effects rather than genital blood flow side effects ^{[8] [6]}. If you want the deeper mechanism explanation, see pt-141 peptide.

What did the FDA actually approve, and for whom?

The FDA approved bremelanotide (Vyleesi) in 2019 as a subcutaneous injection for premenopausal women with acquired, generalized HSDD, low sexual desire that causes personal distress and wasn't always present ^{[1] [4]}. It is not approved for men, for postmenopausal women, or for desire problems caused by a relationship issue, another medical condition, or a medication side effect ^[4]. Approval rested on the two RECONNECT phase 3 trials, both randomized, double-blind, placebo-controlled studies ^[2]. A 2020 Annals of Pharmacotherapy review frames this as the second drug approved for HSDD in the US after flibanserin, and the first delivered by injection rather than a daily pill ^[4]. That's worth sitting with for a second. Two drugs, total, have federal approval for this condition. Anything else marketed for female low desire, whether that's a compounded cream, a supplement, or a nasal spray, sits outside that approved evidence base.

How well does the injection actually work in trials?

Modestly, and the field itself argues about how meaningful that modest effect is. In the RECONNECT trials, roughly 25% of women on bremelanotide reported a meaningful increase in desire versus about 17% on placebo, using responder-defined thresholds reported in a 2019 Journal of Sexual Medicine analysis of a related phase 2b dose-ranging study ^[9]. A subgroup analysis pooling RECONNECT data found consistent direction of effect across age groups and body mass categories, meaning the drug didn't seem to only work for a narrow slice of patients ^[10]. But not every review is impressed. A 2024 Journal of Sex Research paper titled 'Small Effects, Questionable Outcomes' argues the clinically meaningful difference between drug and placebo is thin once you account for the size of the placebo response itself ^[11]. A related 2021 re-analysis in the same journal raises similar concerns about how HSDD outcomes were measured and reported in the phase 3 program ^[12]. A Drug and Therapeutics Bulletin piece goes further, questioning whether the regulatory bar set by an earlier approved drug (flibanserin) should have applied to bremelanotide at all, calling it 'the fallacy of regulatory precedent' ^[13]. This is a legitimate, published disagreement among clinicians and researchers, not fringe skepticism. If you're deciding whether to try it, it's fair to know both sides exist in the literature.

Is there an FDA-approved PT-141 nasal spray?

No. Drugs@FDA, the FDA's own database of approved products, lists bremelanotide only as Vyleesi, an injection ^[14]. There is no approved nasal spray formulation on the market in the US. Any nasal spray labeled PT-141 that you find online is being sold outside that approval, typically as a research chemical or compounded product. Bremelanotide as a raw peptide is not on the FDA's current 503A bulk drug substances list for compounding, which is the list that governs what a compounding pharmacy can legally use to make a patient-specific preparation ^{[15] [16]}. That matters for anyone assuming a compounded spray is functionally the same as the injection with FDA oversight behind it. It isn't the same regulatory situation. A 2020 Pharmaceuticals paper reviewing the FDA's 2019 peptide and oligonucleotide approvals lists Vyleesi among that year's harvest, again as an injectable ^[17]. Every serious pharmacology reference on this drug describes the approved route the same way.

Why did the nasal spray version get dropped in development?

Blood pressure. Early bremelanotide research, including intranasal dosing work published in 2006, moved the compound out of nasal delivery and into subcutaneous injection partly because of dose-related increases in blood pressure seen with higher intranasal exposure ^{[3] [4]}. A 2012 pharmacology paper covering bremelanotide's profile documents this shift in the compound's clinical development path ^[18]. Blood pressure is not a side note for this drug. The FDA label and multiple safety reviews flag transient increases in blood pressure as an expected effect of bremelanotide, tied to its action on melanocortin receptors that influence cardiovascular regulation, more than sexual pathways ^{[8] [19]}. A 2022 Medicina review specifically discusses managing HSDD treatment in women who also have hypertension, because this interaction is clinically relevant enough to need its own guidance ^[19]. So the nasal route wasn't dropped for a trivial reason, like taste or inconvenience. It was dropped because the absorption profile through nasal tissue produced a side effect signal the drug's developers didn't want to carry into an approved product.

How does the approved injection actually get used?

Vyleesi is a subcutaneous, self-administered injection using a single-dose autoinjector, taken as needed, roughly 45 minutes before anticipated sexual activity ^[4]. It is not a daily medication like flibanserin. The RECONNECT trials capped use at one dose within a 24-hour period and no more than 8 doses per month ^[2]. Effects, when present, are meant to last for the encounter it's taken for, not to build up as a chronic desire enhancer over weeks. If you want the specific numbers, timing windows, and how the maximum monthly dosing works, the pt-141 dosage chart breaks that down, and the pt-141 peptide how to use page walks through the injection process step by step. Because dosing is event-driven rather than daily, some people try to estimate dose adjustments themselves, especially with non-pharmacy sourced product. That's a genuinely bad idea without a clinician involved, partly because the safety data below only covers the studied dose and route.

What side effects should you actually expect?

Nausea is the big one. Across the clinical development program, a 2022 Journal of Women's Health safety analysis pooling trial data found nausea was the most common adverse event reported with bremelanotide, alongside flushing and headache ^[8]. These aren't rare footnotes, nausea shows up often enough that trial investigators tracked it as a primary tolerability concern, and some women stopped treatment because of it ^{[2] [8]}. Flushing (a warm, reddened feeling in the face or chest) and injection site reactions were also common in trial reporting ^{[8] [4]}. Blood pressure increases, usually transient, are the effect clinicians watch most closely given the mechanism discussed above ^[19]. A separate line of research looked at bremelanotide's effect on body weight in obese women across two phase 1 trials, finding weight-related metabolic effects tied to melanocortin activation, distinct from the sexual desire indication ^[20]. That's not why Vyleesi is prescribed, but it reflects the same underlying biology, melanocortin receptors sit in appetite regulation too, which a 2023 Nature Reviews Endocrinology paper on central melanocortin targets discusses in a broader metabolic context ^[5]. For a full rundown of what to expect and how long side effects typically last, see pt-141 peptide side effects.

Who should not take bremelanotide, in any form?

Women with uncontrolled high blood pressure or known cardiovascular disease need a real conversation with a prescriber before considering it, because of the transient blood pressure increases tied to its mechanism ^{[19] [8]}. It also isn't approved for postmenopausal women or for men, despite off-label and gray-market use in both groups ^[4]. A 2021 review in the Journal of Midwifery & Women's Health on HSDD physiology and treatment notes that diagnosis itself requires ruling out other causes of low desire, relationship distress, depression, medication side effects, before treatment is appropriate ^[21]. That's a diagnostic step, not paperwork. If low desire is caused by an SSRI, for instance, the fix might be adjusting that medication, not adding bremelanotide on top of it. The trials also excluded certain groups, and safety in pregnancy, breastfeeding, and in women with certain psychiatric or cardiovascular histories hasn't been established the same way it has for the studied population ^{[8] [2]}.

How does bremelanotide compare with flibanserin?

Both are FDA-approved for the same condition in premenopausal women, but they work and are dosed completely differently. | | Bremelanotide (Vyleesi) | Flibanserin (Addyi) |

Where does compounded or gray-market PT-141 fit in?

Legally, it's a gray area, and practically, it's a quality-control gap. Bremelanotide is not currently on the FDA's 503A bulk drug substances list, the list that lets compounding pharmacies use a bulk ingredient to prepare patient-specific medications under 21 U.S.C. 353a ^{[15] [22]}. It's also absent from the parallel 503B list that governs larger outsourcing facilities ^[23]. Products sold as 'PT-141 nasal spray' or 'PT-141 vials' outside a pharmacy relationship are generally marketed as research chemicals, not as drugs intended for human use, which is a legal distinction that matters under 21 CFR 201.128's definition of intended use ^[24]. That labeling dodge doesn't change what people actually do with the product, but it does mean there's no FDA oversight of manufacturing, sterility, or actual peptide content in that vial. If you're weighing a marketplace listing against a legitimate source, the honest comparison is in pt-141 peptide for sale amazon, and it's not a close call on safety grounds. The better path, if bremelanotide seems right for your situation, is talking to a prescriber who can evaluate whether Vyleesi or a provider-reviewed compounded version fits your health history, rather than dosing an unregulated nasal product by guesswork. Bremelanotide Rx exists to connect readers with that provider-reviewed route and a pharmacy partner that actually fulfills prescriptions, not to sell you a spray bottle with no clinical oversight behind it.

Does PT-141 have uses beyond sexual desire?

Research interest goes well beyond HSDD, though none of it is approved for human use in these other areas yet. A 2023 Nature Reviews Endocrinology paper covers central melanocortin targets, including bremelanotide's receptor family, in the context of metabolic disease and weight regulation ^[5]. Separate phase 1 data specifically looked at bremelanotide's effect on body weight in obese women ^[20]. More exploratory still, a 2024 Anticancer Research study found bremelanotide induced cell death and reduced growth in glioblastoma cells in a lab setting, tied to suppression of a protein called survivin ^[25]. That's cell-culture research, not a clinical treatment, and it's a long way from any approved oncology use. A 2025 paper in the Journal of Controlled Release describes a biodegradable suction patch designed for delivering peptides through the cheek lining (transbuccal delivery), an early-stage drug delivery engineering study rather than a bremelanotide-specific clinical result, but it signals ongoing interest in non-injection routes for peptides like this one ^[26]. None of this changes the current approved reality: injection is what's approved, everything else is still research.

Frequently asked questions

Is PT-141 nasal spray FDA-approved?

No. The FDA-approved version of bremelanotide is Vyleesi, a subcutaneous injection, listed in the FDA's Drugs@FDA database ^[24]. No nasal spray formulation has FDA approval. Early development did test intranasal bremelanotide, but that route was set aside during clinical development, reportedly over blood pressure concerns at higher intranasal exposure ^[3][8].

Why did researchers stop developing PT-141 as a nasal spray?

Published pharmacology work points to dose-related blood pressure increases seen with intranasal bremelanotide during early development, which pushed the program toward subcutaneous injection instead ^[1][3][8]. Blood pressure changes remain a known effect of the approved injectable form too, just at a profile the FDA judged acceptable for that route and dose ^[5][22].

How fast does PT-141 injection start working?

Trial protocols had women take the injection about 45 minutes before anticipated sexual activity ^[7]. It's not a background daily medication, it's used as needed, similar in timing concept to how some men's ED medications are taken before activity, though the drug itself works through a different, central mechanism ^[18].

What's the difference between PT-141 and Viagra for arousal?

Viagra (sildenafil) works on blood vessels, improving blood flow to genital tissue. PT-141 (bremelanotide) works on melanocortin receptors in the brain, acting on desire and arousal pathways centrally rather than through blood flow ^[18][19]. That's why bremelanotide is approved for a desire disorder in women, not for a blood-flow-based erectile problem.

Does PT-141 nasal spray actually raise sexual desire?

There's no controlled trial data specifically on a nasal spray formulation's effect on desire. The desire benefit demonstrated in the RECONNECT phase 3 trials was measured using the injectable form, showing modest increases in FSFI desire scores versus placebo ^[11]. Applying that result to an unstudied nasal product is not something the evidence supports.

How common is nausea with bremelanotide?

Common enough to be the most frequently reported adverse event across the clinical development program, according to a pooled 2022 safety analysis ^[5]. Flushing and headache were also frequently reported. Some trial participants discontinued treatment because of these effects, so it's not a minor footnote ^[11][5].

Can men use PT-141?

Vyleesi is only FDA-approved for premenopausal women with HSDD ^[7]. Men do use bremelanotide off-label or through gray-market products for arousal purposes, but this use sits outside the approved indication and outside the controlled trial evidence discussed here, which was all conducted in women.

Is compounded PT-141 nasal spray legal?

Bremelanotide is not currently on the FDA's 503A bulk drug substances list used for pharmacy compounding under 21 U.S.C. 353a ^[9][12], nor on the 503B list for outsourcing facilities ^[13]. Products sold outside a legitimate pharmacy relationship typically market as research chemicals, which carries a different, weaker oversight standard than an approved or properly compounded drug ^[14].

How much does the injection actually help, realistically?

Modestly. RECONNECT trial data showed roughly 25% of women on bremelanotide had a meaningful desire improvement versus about 17% on placebo in related dose-ranging analysis ^[21]. Some published critiques argue this difference is small relative to placebo response and question how clinically meaningful it is ^[20][23].

What's the maximum dose of PT-141 per month?

In the RECONNECT trials, dosing was capped at one dose per 24-hour period and no more than 8 doses per month ^[11]. Exact prescribing guidance should come from a clinician, since individual health factors, especially blood pressure, affect how a dose plan should be set up.

Does PT-141 interact badly with high blood pressure?

It can raise blood pressure transiently, which matters more in people who already have hypertension or cardiovascular disease ^[22][5]. A 2022 Medicina review specifically addresses managing HSDD treatment in women with hypertension, treating this as a real clinical consideration rather than a rare edge case ^[22].

Is bremelanotide the same thing people call 'the female Viagra'?

It's sometimes marketed that way, but the comparison is misleading mechanistically. A 2006 review even asks this question directly in its title ^[4]. Sildenafil works on vascular blood flow; bremelanotide works centrally through melanocortin receptors ^[18][19]. They're both used for sexual function, but through unrelated biology.

Sources

1. PubMed, Bremelanotide (2012): Pharmacology review documenting bremelanotide's clinical development shift away from intranasal dosing
2. Journal of Midwifery & Women's Health, 2021 (PMID 34510696): HSDD diagnosis requires ruling out other causes of low desire before treatment is appropriate
3. PubMed, Bremelanotide (2006): Early pharmacology work tested bremelanotide via intranasal delivery
4. Drugs, Bremelanotide: First Approval, 2019 (PMID 31429064): FDA approved bremelanotide (Vyleesi) in 2019 as a subcutaneous injection
5. Journal of Women's Health, Safety Profile of Bremelanotide, 2022 (PMID 35147466): Nausea, flushing, and injection site reactions are the most common adverse events across the clinical development program
6. Nature Reviews Endocrinology, Targeting the central melanocortin system, 2023 (PMID 37365323): Central melanocortin receptor targeting is studied in metabolic disease and weight regulation contexts
7. The Annals of Pharmacotherapy, Bremelanotide: New Drug Approved for HSDD, 2020 (PMID 31893927): Vyleesi is approved only for premenopausal women with HSDD, dosed as-needed via autoinjector about 45 minutes before activity
8. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: Explains the FDA 503A bulk drug substance list governing what compounding pharmacies may legally use
9. 21 CFR 216.23, the final 503A Bulks List: Federal regulation establishing the 503A bulk drug substances list
10. Obstetrics and Gynecology, Bremelanotide for HSDD: Two Randomized Phase 3 Trials, 2019 (PMID 31599840): RECONNECT phase 3 trial results including FSFI desire score and FSDS-DAO distress score changes, and dosing cap of one dose per 24 hours, max 8 per month
11. 21 U.S.C. 353a, pharmacy compounding: Statute governing pharmacy compounding under section 503A
12. 21 CFR 216.24, the 503B Bulks List: Federal regulation establishing the 503B bulk drug substances list for outsourcing facilities
13. 21 CFR 201.128, meaning of intended uses: Defines intended use, relevant to how research-chemical-labeled products are marketed outside drug regulation
14. Journal of Women's Health, RECONNECT Subgroup Analyses, 2022 (PMID 35230162): Pooled RECONNECT subgroup analysis found consistent direction of treatment effect across age and BMI groups
15. Drug and Therapeutics Bulletin, Bremelanotide and flibanserin: fallacy of regulatory precedent, 2021 (PMID 34642243): Critique questioning whether the regulatory precedent set by flibanserin's approval should apply to bremelanotide
16. Journal of Controlled Release, biodegradable suction patch for transbuccal peptide delivery, 2025 (PMID 40513668): Early-stage drug delivery engineering research into non-injection peptide delivery routes
17. CNS Spectrums, neurobiology of bremelanotide for HSDD, 2022 (PMID 33455598): Bremelanotide's effect on desire in premenopausal women with HSDD is based on a central melanocortin mechanism
18. Biomolecules, Ligands for Melanocortin Receptors, 2022 (PMID 36291616): Bremelanotide activates melanocortin receptors including MC4R, distinct from vascular mechanisms
19. Journal of Sex Research, Small Effects, Questionable Outcomes, 2024 (PMID 36809187): Critique arguing the clinically meaningful difference between bremelanotide and placebo is small
20. The Journal of Sexual Medicine, Responder Analyses from Phase 2b Dose-Ranging Study, 2019 (PMID 31277966): Responder analysis showing roughly 25% of bremelanotide-treated women had meaningful desire improvement versus about 17% on placebo
21. Medicina (Kaunas), Management of Hypertension with Female Sexual Dysfunction, 2022 (PMID 35630054): Clinical guidance on managing HSDD treatment in women who also have hypertension, given bremelanotide's blood pressure effects
22. Journal of Sex Research, Re-Analyzing Phase III Bremelanotide Trials, 2021 (PMID 33678061): Re-analysis raising concerns about how HSDD outcomes were measured and reported in the phase 3 trial program
23. Drugs@FDA, FDA-approved drug products database: Bremelanotide is listed only as Vyleesi, an injectable product, with no approved nasal spray formulation
24. Diabetes, Obesity & Metabolism, Effect of bremelanotide on body weight of obese women, 2022 (PMID 35170192): Phase 1 trial data on bremelanotide's effect on body weight in obese women, separate from the sexual desire indication
25. Pharmaceuticals, 2019 FDA TIDES Harvest, 2020 (PMID 32151051): Review of 2019 FDA peptide and oligonucleotide approvals listing Vyleesi as an injectable product
26. Anticancer Research, Bremelanotide Induces Cell Death in Glioblastoma Cells, 2024 (PMID 39197897): Lab study found bremelanotide induced cell death and growth inhibition in glioblastoma cells via survivin suppression